CARGO Therapeutics, Inc.
CRGX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CRGX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2025.
Tracking 1 pipeline candidate · 1 clinical trial for CARGO Therapeutics, Inc..
Run CARGO Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CARGO Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
9.6 months
D/E 0.09
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is CARGO Therapeutics, Inc.'s lead drug candidate?
CARGO Therapeutics, Inc.'s most advanced tracked candidate is firi-cel (Phase 2) for Cancer.
Who is the CEO of CARGO Therapeutics, Inc.?
Dear Stockholder is the chief executive officer of CARGO Therapeutics, Inc. (CRGX).
What therapeutic areas does CARGO Therapeutics, Inc. focus on?
CARGO Therapeutics, Inc. develops therapies across Oncology, Gene Therapy.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.